Arena Pharmaceuticals to Present at the Granite Financial Group Healthcare Investors Conference
SAN DIEGO, Nov 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) today announced that it will present a corporate update at the
Granite Financial Group Healthcare Investors Conference on Thursday,
November 18, 2004, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time).
Dominic P. Behan, Ph.D., Chief Scientific Officer & Senior Vice President,
will give the presentation, which will be webcast live over the Internet. The
conference will be held at the Del Mar Marriott in San Diego.
To access the live or archived presentation, simply log on to the
following link http://www.vcall.com/CEPage.asp?ID=89711 or www.arenapharm.com
under the investor relations section. Please connect to either one of the
websites several minutes prior to the start of the broadcast to ensure
adequate time for any software download that may be necessary. The
presentation will be archived for 30 days on both websites.
About Arena Pharmaceuticals
Arena is a biopharmaceutical company focusing on the discovery,
development and commercialization of drugs in four major therapeutic areas:
metabolic, cardiovascular, inflammatory and central nervous system diseases.
Arena is developing a broad pipeline of compounds that act on an important
class of drug targets called G protein-coupled receptors, or GPCRs, and that
are being developed using Arena's proprietary technologies, including CART
(Constitutively Activated Receptor Technology) and Melanophore. Arena also
has research collaborations with Merck, Fujisawa, Taisho and TaiGen for
products in a number of different indications. For additional information
about Arena, visit their website at http://www.arenapharm.com.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about Arena's strategy, technologies,
preclinical and clinical programs, ability to identify and develop drugs,
future achievements, goals and expectations, as well as other statements that
are not historical facts. For such statements, Arena claims the protection of
the Private Securities Litigation Reform Act of 1995. Actual events or
results may differ materially from Arena's expectations. Factors that could
cause actual results to differ materially from the forward-looking statements
include, but are not limited to, the timing, success and cost of Arena's
research, out-licensing endeavors and clinical studies, Arena's ability to
obtain additional financing, and the timing and receipt of payments and fees,
if any, from Arena's collaborators. Additional factors that could cause
actual results to differ materially from those stated or implied by Arena's
forward-looking statements are disclosed in Arena's SEC reports, including
Arena's most recent quarterly report on Form 10-Q. These forward-looking
statements represent Arena's judgment as of the date of this release. Arena
disclaims any intent or obligation to update these forward-looking statements.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company.
For more information, please contact: Jack Lief of Arena Pharmaceuticals,
+1-858-453-7200; or Susan Neath of Atkins + Associates, +1-858-527-3486, for